<HTML>


<HEAD>








<TITLE>Word 8.0 Generic Normal Template, rev. 4/1/97, The Legal MacPac</TITLE>


</HEAD>


<BODY LINK="#0000ff" VLINK="#800080">





<P ALIGN="JUSTIFY"></P>


<B><P ALIGN="CENTER">UNITED STATES<BR>


SECURITIES AND EXCHANGE COMMISSION<BR>


Washington, D.C. 20549</P>


</B><P ALIGN="JUSTIFY">&nbsp;</P>


<B><FONT SIZE=5><P ALIGN="CENTER">FORM 8-K </P>


</FONT><P ALIGN="CENTER">CURRENT REPORT<BR>


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</P>


</B><FONT SIZE=2><P ALIGN="CENTER">Date of Report (Date of earliest event reported):<B>  February 17, 2006</P>


</B></FONT><P ALIGN="JUSTIFY">&nbsp;</P>


<B><FONT SIZE=6><P ALIGN="CENTER">CONOR MEDSYSTEMS, INC.</FONT><FONT SIZE=5><BR>


</B></FONT><FONT SIZE=2>(Exact name of registrant as specified in its charter) </P>


<B><P ALIGN="CENTER">Delaware</B><BR>


(State or other jurisdiction of incorporation) </P></FONT>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=624>


<TR><TD WIDTH="49%" VALIGN="TOP">


<B><FONT SIZE=2><P ALIGN="CENTER">000-51066</B></FONT></TD>


<TD WIDTH="3%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>


<TD WIDTH="48%" VALIGN="TOP">


<B><FONT SIZE=2><P ALIGN="CENTER">94-3350973</B></FONT></TD>


</TR>


<TR><TD WIDTH="49%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="CENTER">(Commission File Number)</FONT></TD>


<TD WIDTH="3%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>


<TD WIDTH="48%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="CENTER">(IRS Employer Identification No.)</FONT></TD>


</TR>


</TABLE>





<B><FONT SIZE=2><P ALIGN="CENTER">1003 Hamilton Court</P>


<P ALIGN="CENTER">Menlo Park, CA 94025<BR>


</B>(Address of principal executive offices, including Zip Code) </P>


<P ALIGN="CENTER">Registrant's telephone number, including area code: <B>(650) 614-4100</P>


</B></FONT><P ALIGN="CENTER"></P>


<FONT SIZE=2><P>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>


<P><FONT FACE="Wingdings">&#168;</FONT>


&#9;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>


<P><FONT FACE="Wingdings">&#168;</FONT>


&#9;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>


<P><FONT FACE="Wingdings">&#168;</FONT>


&#9;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>


<P><FONT FACE="Wingdings">&#168;</FONT>


&#9;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>


</FONT>


<B><FONT SIZE=3><P ALIGN="JUSTIFY">Item 8.01.&#9;Other Events.</P>


</B><P ALIGN="JUSTIFY">On February 17, 2006, Conor Medsystems, Inc. (the &quot;Company&quot;) announced that it received Conformite Europeen (CE) Mark approval for its CoStar&trade; cobalt chromium paclitaxel-eluting stent for the treatment of coronary artery disease.  CE Mark approval enables the Company to commercialize its CoStar stent in the European Union and other countries accepting CE Mark. Beginning immediately, the Company's CoStar stent will be marketed and distributed in these markets by Biotronik AG.</P>


<P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">&nbsp;</P>


<B><P ALIGN="CENTER">&nbsp;</P>


</FONT><FONT SIZE=2><P ALIGN="CENTER">SIGNATURES </P>


</B><P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </P></FONT>


<TABLE CELLSPACING=0 BORDER=0 WIDTH=624>


<TR><TD WIDTH="47%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>


<TD WIDTH="3%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY">&nbsp;</FONT></TD>


<TD WIDTH="50%" VALIGN="TOP" COLSPAN=3>


<B><FONT SIZE=2><P ALIGN="JUSTIFY">CONOR MEDSYSTEMS, INC.</B></FONT></TD>


</TR>


<TR><TD WIDTH="47%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY"><BR>


</P>


<P ALIGN="JUSTIFY">Dated: February 17, 2006</FONT></TD>


<TD WIDTH="3%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY"><BR>


&nbsp;</FONT></TD>


<TD WIDTH="4%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY"><BR>


By:</FONT></TD>


<TD WIDTH="1%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY"><BR>


&nbsp;</FONT></TD>


<TD WIDTH="45%" VALIGN="TOP">


<FONT SIZE=2><P ALIGN="JUSTIFY"></P>


<P ALIGN="JUSTIFY">/s/ Michael Boennighausen</P>


<P ALIGN="CENTER"></P>


<P ALIGN="CENTER">Michael Boennighausen<BR>


<I>Vice President and Chief Financial Officer</I></FONT></TD>


</TR>


</TABLE>





<B><FONT SIZE=3><P ALIGN="CENTER"></P>


</B></FONT><P> </P>


</BODY>


</HTML>
[{"type": "8-K", "sequence": "1", "filename": "rrd108647.htm", "secsgml_size_bytes": 4785}]
{"company-data": {"conformed-name": "CONOR MEDSYSTEMS INC", "cik": "0001108271", "assigned-sic": "3841", "irs-number": "943350973"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51066", "film-number": "06629691"}, "business-address": {"street1": "1003 HAMILTON COURT", "city": "MENLO PARK", "state": "CA", "zip": "94025", "phone": "(650) 614-4100"}, "mail-address": {"street1": "1003 HAMILTON COURT", "city": "MENLO PARK", "state": "CA", "zip": "94025"}}
Word 8.0 Generic Normal Template, rev. 4/1/97, The Legal MacPac
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 17, 2006
CONOR MEDSYSTEMS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
000-51066
94-3350973
(Commission File Number)
(IRS Employer Identification No.)
1003 Hamilton Court
Menlo Park, CA 94025
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code:
(650) 614-4100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01.	Other Events.
On February 17, 2006, Conor Medsystems, Inc. (the "Company") announced that it received Conformite Europeen (CE) Mark approval for its CoStar™ cobalt chromium paclitaxel-eluting stent for the treatment of coronary artery disease.  CE Mark approval enables the Company to commercialize its CoStar stent in the European Union and other countries accepting CE Mark. Beginning immediately, the Company's CoStar stent will be marketed and distributed in these markets by Biotronik AG.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CONOR MEDSYSTEMS, INC.
Dated: February 17, 2006
By:
/s/ Michael Boennighausen
Michael Boennighausen
Vice President and Chief Financial Officer